首頁 > 市場調查報告書 > 製藥

藥物開發臨床實驗開發業務受託機關

市場調查報告書

商品編碼

1609872

2025-2033 年日本臨床前 CRO 市場報告（按服務（生物分析和 DMPK 研究、毒理學測試等）、最終用途（生物製藥公司、政府和學術機構、醫療器材公司）和地區

Japan Preclinical CRO Market Report by Service (Bioanalysis and DMPK Studies, Toxicology Testing, and Others), End Use (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies), and Region 2025-2033

出版日期: 2024年12月05日 | 出版商:

IMARC | 英文 116 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024 年，日本臨床前 CROIMARC Group規模達到 2.432 億美元。由於公司更加重視其核心優勢以及最近在專業治療方面的突破，市場正在見證巨大的發展勢頭。

臨床前合約研究組織 (CRO) 是一家為生物技術、製藥和醫療器材領域提供多樣化研發 (R&D) 服務的公司。這些服務涵蓋廣泛，包括毒理學研究、藥物動力學評估、製劑開發、監管協助和藥效研究。臨床前CRO服務的應用涵蓋多個領域，包括藥物發現、醫療器材評估、生物相容性評估、疾病建模、安全藥理學研究以及合適劑型的選擇。這些服務有助於加速產品開發、加強對監管要求的遵守、利用專業知識、最佳化資源分配並提供靈活的研究解決方案。

日本臨床前CRO市場趨勢：

在日本市場背景下，企業越來越重視專注於發展自己的核心競爭力。這一趨勢正在推動對臨床前合約研究組織(CRO) 的需求，因為它們使公司能夠委託專門的臨床前任務，從而使他們能夠將更多資源分配到其主要關注領域，例如後期臨床試驗或行銷工作。此外，日本對臨床前 CRO 服務的需求激增與新興經濟體製藥業的快速擴張有關，而新興經濟體的製藥業需要解決獨特的醫療保健挑戰並滿足不斷成長的患者群體的需求。此外，市場受益於個人化醫療、生物製劑和基因療法等專業治療的最新進展，這需要精確而細緻的臨床前測試。此外，臨床前 CRO 的廣泛採用是出於採用風險平衡方法的願望，特別是考慮到藥物開發的高失敗率。最後，在成功執行臨床前研究中發揮關鍵作用的尖端技術的引入預計將在預測期內提振日本市場的成長前景。

日本臨床前CRO市場細分：

服務洞察：

生物分析和 DMPK 研究
毒理學測試
其他

最終用途見解：

生物製藥公司
政府和學術機構
醫療器材公司

競爭格局：

市場研究報告也對競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀表板和公司評估象限等競爭分析。此外，也提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本臨床前 CRO 市場迄今表現如何，未來幾年又將如何表現？
COVID-19 對日本臨床前 CRO 市場有何影響？
日本臨床前CRO市場以服務為基礎的細分是怎樣的？
日本臨床前 CRO 市場以最終用途分類是怎樣的？
日本臨床前CRO市場價值鏈的各個階段是什麼？
日本臨床前CRO的關鍵促進因素與挑戰是什麼？
日本臨床前CRO市場的結構如何？
日本臨床前CRO市場的競爭程度如何？

本報告回答的關鍵問題：

日本臨床前 CRO 市場迄今表現如何，未來幾年又將如何表現？
COVID-19 對日本臨床前 CRO 市場有何影響？
日本臨床前CRO市場以服務為基礎的細分是怎樣的？
日本臨床前 CRO 市場以最終用途分類是怎樣的？
日本臨床前CRO市場價值鏈的各個階段是什麼？
日本臨床前CRO的關鍵促進因素與挑戰是什麼？
日本臨床前CRO市場的結構如何？
日本臨床前CRO市場的競爭程度如何？

生物製藥公司
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
政府和學術機構
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）
醫療器材公司
- 概述
- 歷史與當前市場趨勢（2019-2024）
- 市場預測（2025-2033）

第 8 章：日本臨床前 CRO 市場 - 競爭格局

概述
市場結構
市場參與者定位
最佳制勝策略
競爭儀表板
公司評估象限

第 9 章：關鍵參與者簡介

Company A

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company B

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company C

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company D

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

Company E

Business Overview
Product Portfolio
Business Strategies
SWOT Analysis
Major News and Events

第 10 章：日本臨床前 CRO 市場 - 產業分析

促進因素、限制因素和機會
- 概述
- 促進要素
- 限制
- 機會
波特五力分析
- 概述
- 買家的議價能力
- 供應商的議價能力
- 競爭程度
- 新進入者的威脅
- 替代品的威脅
價值鏈分析

第 11 章：附錄

簡介目錄

Product Code: SR112024A18712

Japan preclinical CRO market size reached USD 243.2 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 539.9 Million by 2033, exhibiting a growth rate (CAGR) of 8.3% during 2025-2033. The market is witnessing significant momentum due to a heightened emphasis among companies on their core strengths and recent breakthroughs in specialized treatments.

A preclinical contract research organization (CRO) is a company that delivers diverse research and development (R&D) services to the biotechnology, pharmaceutical, and medical device sectors. These services encompass a wide spectrum, including toxicology investigations, pharmacokinetic assessments, formulation development, regulatory assistance, and pharmacodynamic studies. The applications of preclinical CRO services span various domains, encompassing drug discovery, medical device evaluation, biocompatibility assessments, disease modeling, safety pharmacology investigations, and the selection of appropriate dosage forms. These services facilitate the acceleration of product development, bolster compliance with regulatory requirements, tap into specialized expertise, optimize resource allocation, and offer flexible research solutions.

Japan Preclinical CRO Market Trends:

In the context of the Japanese market, there is an increasing emphasis among companies on concentrating their efforts on their core competencies. This trend is driving the demand for preclinical contract research organizations (CROs) as they enable companies to delegate specialized preclinical tasks, allowing them to allocate more resources to their primary areas of focus, such as late-phase clinical trials or marketing endeavors. Moreover, the surging demand for preclinical CRO services in Japan is linked to the rapid expansion of the pharmaceutical sector in emerging economies, driven by the need to address unique healthcare challenges and cater to a growing patient population. Additionally, the market is benefiting from recent advancements in specialized treatments like personalized medicine, biologics, and gene therapies, which necessitate precise and nuanced preclinical testing. Furthermore, the widespread adoption of preclinical CROs is driven by the desire to adopt a risk-balanced approach, especially in light of the high failure rate in drug development. Lastly, the introduction of cutting-edge technologies that play a pivotal role in the successful execution of preclinical studies is expected to bolster the market's growth prospects in Japan over the forecasted period.

Japan Preclinical CRO Market Segmentation:

Service Insights:

Bioanalysis and DMPK Studies
Toxicology Testing
Others

End Use Insights:

Biopharmaceutical Companies
Government and Academic Institutes
Medical Device Companies

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan preclinical CRO market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan preclinical CRO market?
What is the breakup of the Japan preclinical CRO market on the basis of service?
What is the breakup of the Japan preclinical CRO market on the basis of end use?
What are the various stages in the value chain of the Japan preclinical CRO market?
What are the key driving factors and challenges in the Japan preclinical CRO?
What is the structure of the Japan preclinical CRO market and who are the key players?
What is the degree of competition in the Japan preclinical CRO market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Preclinical CRO Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Preclinical CRO Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Preclinical CRO Market - Breakup by Service

6.1 Bioanalysis and DMPK Studies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Toxicology Testing
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Others
- 6.3.1 Historical and Current Market Trends (2019-2024)
- 6.3.2 Market Forecast (2025-2033)

7 Japan Preclinical CRO Market - Breakup by End Use

7.1 Biopharmaceutical Companies
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Government and Academic Institutes
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Medical Device Companies
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)

8 Japan Preclinical CRO Market - Competitive Landscape

8.1 Overview
8.2 Market Structure
8.3 Market Player Positioning
8.4 Top Winning Strategies
8.5 Competitive Dashboard
8.6 Company Evaluation Quadrant

9 Profiles of Key Players

9.1 Company A
- 9.1.1 Business Overview
- 9.1.2 Product Portfolio
- 9.1.3 Business Strategies
- 9.1.4 SWOT Analysis
- 9.1.5 Major News and Events
9.2 Company B
- 9.2.1 Business Overview
- 9.2.2 Product Portfolio
- 9.2.3 Business Strategies
- 9.2.4 SWOT Analysis
- 9.2.5 Major News and Events
9.3 Company C
- 9.3.1 Business Overview
- 9.3.2 Product Portfolio
- 9.3.3 Business Strategies
- 9.3.4 SWOT Analysis
- 9.3.5 Major News and Events
9.4 Company D
- 9.4.1 Business Overview
- 9.4.2 Product Portfolio
- 9.4.3 Business Strategies
- 9.4.4 SWOT Analysis
- 9.4.5 Major News and Events
9.5 Company E
- 9.5.1 Business Overview
- 9.5.2 Product Portfolio
- 9.5.3 Business Strategies
- 9.5.4 SWOT Analysis
- 9.5.5 Major News and Events

10 Japan Preclinical CRO Market - Industry Analysis

10.1 Drivers, Restraints, and Opportunities
- 10.1.1 Overview
- 10.1.2 Drivers
- 10.1.3 Restraints
- 10.1.4 Opportunities
10.2 Porters Five Forces Analysis
- 10.2.1 Overview
- 10.2.2 Bargaining Power of Buyers
- 10.2.3 Bargaining Power of Suppliers
- 10.2.4 Degree of Competition
- 10.2.5 Threat of New Entrants
- 10.2.6 Threat of Substitutes
10.3 Value Chain Analysis